Document is current
Any future updates will be listed below
-
Authors
Orsi, Emanuela
Penno, Giuseppe
Solini, Anna
Bonora, Enzo
Fondelli, Cecilia
Trevisan, Roberto
Vedovato, Monica
Cavalot, Franco
Morano, Susanna
Baroni, Marco G.
Nicolucci, Antonio
Pugliese, Giuseppe https://orcid.org/0000-0003-1574-0397
,
Pugliese, Giuseppe
Penno, Giuseppe
Solini, Anna
Bonora, Enzo
Orsi, Emanuela
Trevisan, Roberto
Laviola, Luigi
Nicolucci, Antonio
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00715481 at ClinicalTrials.govDocuments that mention this clinical trial
Independent association of atherogenic dyslipidaemia with all‐cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study
https://doi.org/10.1186/s12933-021-01224-7
Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1007/s00592-018-1133-z
Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study
https://doi.org/10.1136/bmjdrc-2020-001481
Risk of all-cause mortality according to the European Society of Cardiology risk categories in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1007/s00592-022-01942-8
Prognostic impact of switching to the 2021 chronic kidney disease epidemiology collaboration creatinine-based equation in Caucasian patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular events (RIACE) Italian Multicenter Study
https://doi.org/10.1186/s12933-024-02450-5
Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1371/journal.pone.0125512
Body mass index versus surrogate measures of central adiposity as independent predictors of mortality in type 2 diabetes
https://doi.org/10.1186/s12933-022-01706-2
-
Funding
Funding for this research was provided by:
Diabete Ricerca
Diabetes, Endocrinology and Metabolism Foundation
Eli Lilly and Company
Boehringer Ingelheim
Takeda Pharmaceutical Company
Chiesi Farmaceutici
Sigma-Tau Pharmaceuticals
- License Information
-
More Information
Article History
Received: 30 November 2020
Accepted: 22 January 2021
First Online: 30 January 2021
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki. The research protocol was approved by the ethics committee of the coordinating centre (Sant’Andrea Hospital, Rome, Italy) on 25 September 2006 (number 43/2006) and subsequently by the ethics committee of each participating centre. Participants provided an informed consent.
: Not applicable.
: EO: consulting fees from Eli Lilly and Novo Nordisk; GPe: lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Sigma-Tau, and Takeda, and travel grants from AstraZeneca, Novo Nordisk, and Takeda; AS: consulting fees from AstraZeneca, Boehringer Ingelheim, and Sanofi-Aventis, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and MundiPharma; EB: consulting fees from Abbot, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Bruno Farmaceutici, Eli Lilly, Janssen, Johnson&Johnson, Merck Sharp & Dohme, MundiPharma, Novartis, Novo Nordisk, Roche, Sanofi-Aventis, Servier, and Takeda, and research grants from AstraZeneca, Genzyme, Menarini Diagnostics, Novo Nordisk, Roche, and Takeda; CF: lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk and travel grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Sanofi-Aventis, and Takeda; RT: consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi-Aventis, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; MV: lecture fees from Lifescan and Novo Nordisk; FC: lecture fees from AstraZeneca, Sanofi-Aventis, and Takeda; SM: lecture fees from AstraZeneca, Sanofi-Aventis, and Takeda; MB: lecture fees from Abbot, Astra-Zeneca, Mundi Pharma, Novo Nordisk, Sanofi-Aventis; grant support from Sanofi-Aventis; AN: consulting fees from AstraZeneca, Pikdare, and Roche, lecture fees from AstraZeneca, Boehringer Ingelheim, Medtronic, and Novo Nordisk, and research grants from Aboca, AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi-Aventis, and Theras; GPu: consulting fees from AstraZeneca, Boehringer Ingelheim, and Eli Lilly, lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, MundiPharma, Novartis, Novo Nordisk, Sigma-Tau, Takeda, and travel grants from AstraZeneca, Laboratori Guidotti, Sanofi-Aventis, and Takeda.
